Robert W. Baird rated Buy Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) on 08/03/2007, when the stock price was $11.26. Since then, Infinity Pharmaceuticals, Inc. has lost 19.01% as of 01/25/2016's recent price of $9.12.
If you would have followed this Robert W. Baird's recommendation on INFI, you would have lost 19% of your investment in 3097 days.

Infinity Pharmaceuticals, Inc. (IPI) has developed a pipeline of product candidates for multiple cancer indications. The Company?s lead product candidate, retaspimycin hydrochloride (IPI-504) is an intravenously-administered small molecule inhibitor of heat shock protein 90 (Hsp90). Hsp90 is a central component of the cellular chaperone system, which supports and stabilizes cancer-causing proteins, such as c-Kit, EGFR, and HER2, enabling multiple forms of cancer to thrive. Inhibition of the Hsp90 chaperone knocks out this critical source of support for cancer cells, leading to tumor growth inhibition and cancer cell death. In October 2008, the commenced an international Phase III registration study of IPI-504 in patients with refractory gastrointestinal stromal tumors (GIST), based on the activity and safety data from a Phase I trial reported during the year ended December 31, 2008.

Deep, comprehensive coverage is essential to your success. And with nearly 100 research professionals covering over 500 U.S. companies, our reputation for trusted, award-winning, in-depth analysis with a strong commitment to objective, fundamental research speaks for itself.

Marked as spam